TCM Biotech International (ROCO:4169) EV-to-EBIT : 117.02 (As of Jun. 19, 2024)

View and export this data going back to 2012. Start your Free Trial

What is TCM Biotech International EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, TCM Biotech International's Enterprise Value is NT$2,902.4 Mil. TCM Biotech International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$24.8 Mil. Therefore, TCM Biotech International's EV-to-EBIT for today is 117.02.

The historical rank and industry rank for TCM Biotech International's EV-to-EBIT or its related term are showing as below:

ROCO:4169' s EV-to-EBIT Range Over the Past 10 Years
Min: 24.17 Med: 81.63 Max: 448.27
Current: 117.01

During the past 13 years, the highest EV-to-EBIT of TCM Biotech International was 448.27. The lowest was 24.17. And the median was 81.63.

ROCO:4169's EV-to-EBIT is ranked worse than
94.21% of 432 companies
in the Biotechnology industry
Industry Median: 8.975 vs ROCO:4169: 117.01

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. TCM Biotech International's Enterprise Value for the quarter that ended in Dec. 2023 was NT$3,056.0 Mil. TCM Biotech International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$24.8 Mil. TCM Biotech International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.81%.

TCM Biotech International EV-to-EBIT Historical Data

The historical data trend for TCM Biotech International's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCM Biotech International EV-to-EBIT Chart

TCM Biotech International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

76.06

47.73

461.08

62.04

123.20

TCM Biotech International Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															461.08	-	62.04	-	123.20

Competitive Comparison of TCM Biotech International's EV-to-EBIT

For the Biotechnology subindustry, TCM Biotech International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TCM Biotech International's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCM Biotech International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TCM Biotech International's EV-to-EBIT falls into.

TCM Biotech International EV-to-EBIT Calculation

TCM Biotech International's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2902.446	/	24.804
	=	117.02

TCM Biotech International's current Enterprise Value is NT$2,902.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TCM Biotech International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$24.8 Mil.

TCM Biotech International (ROCO:4169) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

TCM Biotech International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	24.804	/	3055.97152
	=	0.81 %

TCM Biotech International's Enterprise Value for the quarter that ended in Dec. 2023 was NT$3,056.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. TCM Biotech International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was NT$24.8 Mil.

TCM Biotech International EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of TCM Biotech International's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

TCM Biotech International (ROCO:4169) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCM Biotech International Corp (ROCO:4169) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 97, Sec. 1, Xintai 5th Road, Xizhi District, Neihu District, Taipei, TWN, 221

Website

http://www.tcmbio.com

TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.

TCM Biotech International (ROCO:4169) Headlines

No Headlines